Cough syrup deaths: India's drug regulator inspected 90% of cough syrup makers, found lapses, says official

India's drug regulator has undertaken a comprehensive inspection of cough syrup manufacturers across the country, revealing significant compliance issues. Following a series of child deaths allegedly linked to tainted cough syrups, authorities intensified scrutiny, inspecting 90% of the companies in the sector. This proactive measure underscores the regulator's commitment to ensuring pharmaceutical safety and protecting public health. The inspections unearthed a variety of lapses, ranging from inadequate quality control measures to improper documentation and labeling practices. Such findings highlight systemic challenges within the pharmaceutical manufacturing sector, raising concerns about the broader implications for drug safety standards in India. These lapses have prompted calls for stricter regulatory oversight and more rigorous enforcement of existing laws to prevent similar incidents in the future. In response to these alarming findings, the Indian government is reportedly considering a series of reforms aimed at tightening regulatory frameworks and enhancing the accountability of pharmaceutical companies. These potential reforms could include more frequent inspections, harsher penalties for non-compliance, and increased transparency in the manufacturing process. As the investigation continues, stakeholders are urged to prioritize safety to restore public confidence in the nation's pharmaceutical products.

— Authored by Next24 Live